The MarketWatch News Department was not involved in the creation of this content.
Dec 04, 2020 (The Expresswire) —
The global “Nuclear Medicine/Radiopharmaceuticals Market” size is projected to reach USD 9.67 billion by 2026. According to a report published by Fortune Business Insights, titled “Nuclear Medicine/Radiopharmaceuticals Market Size, Share and Industry Analysis, By Type (Diagnostic Radiopharmaceuticals, Therapeutic Radiopharmaceuticals), By Application (Neurology, Cardiology, Oncology, and Others), By End User (Hospitals and Clinics, Diagnostic Centres, and Others) and Regional Forecast, 2019-2026,” the market was valued at USD 4.86 billion in 2018. Driven by increasing number of successful clinical trials, the market will exhibit a CAGR of 9.2% from 2019-2026.
Leading Players operating in the Nuclear Medicine/ Radiopharmaceuticals Market are:
Key players are involved in mergers and acquisition to strengthen their market position. Owing to increasing competition frequent innovations are taking place in the market. Some of the companies operating the industry are:
- Lantheus Medical Imaging, Inc.
- Cardinal Health
- Norgine B.V.
- Advanced Accelerator Applications (Novartis AG)
- Bracco Diagnostic Inc.
- Jubilant Life Sciences Limited
- Bayer AG
- Eli Lilly and Company
- GE Healthcare (General Electric Company)
Request a Sample Copy of the Research Report:https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/nuclear-medicine-radiopharmaceuticals-market-101812
Radiopharmaceuticals are substances that are used to diagnose specific medical problems or diseases. Increasing imaging capabilities and efficiencies have led to a wide product adoption across the world. Increasing number of successful clinical trials associated with radiopharmaceuticals will fuel the demand for the product. Recent drug application area discoveries have showcased promise for the companies operating in the market. Technological advancements in nuclear imaging and their applications in diagnosis of cancer and other serious diseases have opened up a huge potential for growth. Growing awareness regarding the adverse effects of chronic diseases, and the need for early diagnosis will aid market growth.
The advancements in imaging systems have played a major role in the growth of the market. Companies are putting in increased efforts towards the manufacturing of diagnostic radiopharmaceuticals. Increasing investments in the research and development (RandD) will create several growth opportunities for market growth. At the same instance, therapeutic radiopharmaceuticals can be used for the treatment of critical illnesses such as cancers.
Have Any Query? Ask Our Experts:https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/nuclear-medicine-radiopharmaceuticals-market-101812
Detailed Table of Content:
- Research Scope
- Market Segmentation
- Research Methodology
- Definitions and Assumptions
- Executive Summary
- Market Drivers
- Market Restraints
- Market Opportunities
- Installed Base of PET/PET-CT Scanners For Key Countries, 2015 and 2018
- Installed Base of Gamma Cameras for Key Countries, 2018
- PET/PET-CT Procedure Volume for Key Countries, 2018
- Reimbursement Scenario in Key Countries
- New Product Launches
- Key Industry Developments
- Pipeline Analysis
Global Nuclear Medicine/ Radiopharmaceuticals Market Analysis, Insights and Forecast, 2015-2026
- Key Findings / Summary
Market Analysis, Insights and Forecast By Type
- Therapeutic Radiopharmaceuticals
- PET Radiopharmaceuticals
Market Analysis, Insights and Forecast By Application
Market Analysis, Insights and Forecast By End User
- Hospitals and Clinics
- Diagnostic Centers
Market Analysis, Insights and Forecast By Region
- Diagnostic Radiopharmaceuticals